Timeline

1. 29 days ago

   [BUSINESS] 2 sources

   BioMarin Pharmaceutical to acquire Alesta Therapeutics

   BioMarin Pharmaceutical will acquire Alesta Therapeutics for up to $490 million to secure ALE1, a potential first-of-its-kind oral treatment for the rare genetic disease hypophosphatasia.

2. about 1 month ago

   [BUSINESS] 2 sources

   Mereo BioPharma and Sentynl Therapeutics partner on alvelestat licensing

   Mereo BioPharma and Sentynl Therapeutics have signed a licensing deal for alvelestat, a potential first oral treatment for the rare lung disease AATD-LD.

Sources

corrierenazionale.it · innlifes.com